

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code		
A A		12/135,025		Chevrier et al.	N/A
A B		12/170,333		Yu et al.	N/A
A C		12/186,404		Chevrier et al.	N/A
A D		60/132,892		Shu	N/A
A E		60/201,012		Shu	N/A
A F		60/204,039		Theill	N/A
A G		60/214,591		Theill	N/A
A H		60/312,808		Gelfanova	N/A
A I		2001/0010925	A1	Wiley	08/02/2001
A J		2002/0055624	A1	Wiley	05/09/2002
A K		2002/0115112	A1	Yu et al.	08/22/2002
A L		2003/0012783	A1	Kindsvogel	01/16/2003
A M		2003/0022233	A1	Goodwin	01/30/2003
A N		2003/0091565	A1	Beltzer et al.	05/15/2003
A O		2003/0175208	A1	Yu et al.	09/18/2003
A P		2003/0223996	A1	Ruben et al.	12/04/2003
A Q		2004/0175801	A1	Yu et al.	09/09/2004
A R		2004/0175802	A1	Yu et al.	09/09/2004
A S		2005/0070694	A1	Gelfanova et al.	03/31/2005
A T		2005/0186637	A1	Yu et al.	08/25/2005
A U		2005/0255532	A1	Ruben et al.	11/17/2005
A V		2006/0062789	A1	Ruben et al.	03/23/2006
A W		2006/0084608	A1	Beltzer et al.	04/20/2006
A X		2006/0171919	A1	Rosenblum et al.	08/03/2006
A Y		2006/0193859	A1	Yu et al.	08/31/2006
A Z		2006/0198784	A1	Yu et al.	09/07/2006
B A		2007/0086979	A1	Chevrier et al.	04/19/2007
B B		2007/0212733	A1	Martin	09/13/2007
B C		2009/0068201	A1	Yu et al.	03/12/2009
B D		4,179,337		Davis et al.	12/18/1979
B E		5,223,409		Ladner et al.	06/29/1993
B F		5,281,704		Love	01/25/1994
B G		5,403,484		Ladner et al.	04/04/1995
B H		5,474,981		Leder et al.	12/12/1995
B I		5,571,698		Ladner et al.	11/05/1996
B J		5,576,195		Robinson et al.	11/19/1996
B K		5,605,671		Lyle	02/25/1997
B L		5,635,384		Walsh et al.	06/03/1997
B M		5,643,575		Martinez et al.	07/01/1997
B N		5,795,724		Hillman et al.	08/18/1998
B O		5,846,818		Robinson et al.	12/08/1998
B P		5,869,045		Hellstrom et al.	02/09/1999
B Q		5,969,102		Bram et al.	10/19/1999

Examiner Signature

Date Considered

If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office. (Continued on next page if necessary)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
B R	6,475,987	B1	Shu		11/05/2002	
B S	6,541,224	B2	Yu		04/01/2003	
B T	6,774,106	B1	Theill		08/10/2004	
B U	6,812,327	B1	Yu		11/02/2004	
B V	6,846,476	B2	White		04/04/2002	
B W	6,881,401	B1	Yu		04/19/2005	
B X	7,118,872	B2	Beltzer et al.		10/10/2006	
B Y	7,138,501	B2	Ruben et al.		11/21/2006	
B Z	7,220,840	B2	Ruben et al.		05/22/2007	
C A	7,259,137	B2	Min et al.		08/21/2000	
C B	7,317,089	B2	Kikly		01/08/2008	
C C	7,399,593		Farrow et al.		07/15/2008	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation *
		Office	Application or Patent Number	Kind Code			
C D	WO 93/21232	A1	Research Development Foundation		10/28/1993		
C E	WO 94/20540	A1	Universidad De Valladolid		09/15/1994		
C F	WO 95/07297	A1	Menarini Ricerche SUD S.P.A.		03/16/1995		
C G	WO 95/20398	A1	Human Genome Sciences, Inc.		8/3/1995		
C H	WO 95/24466	A1	Human Genome Sciences, Inc.		9/14/1995		
C I	WO 95/24414	A1	Human Genome Sciences, Inc.		9/14/1995		
C J	WO 97/34911	A1	Human Genome Sciences, Inc.		9/25/1997		
C K	WO 95/31468	A1	Human Genome Sciences, Inc.		11/23/1995		
C L	WO 96/14328	A1	Human Genome Sciences, Inc.		5/17/1996		
C M	WO 96/34095	A1	Human Genome Sciences, Inc.		10/31/1996		
C N	WO 97/46251	A1	LaJolla Pharmaceutical Company		12/11/1997		
C O	WO 97/49726	A1	Ministero Universita' Ricerca Scientifica E Tecnologica		12/31/1997		
C P	WO 98/07880	A1	Human Genome Sciences, Inc.		2/26/1998		
C Q	WO 98/50547	A2	Schering Corporation		11/12/1998		
C R	WO 98/55623	A1	Tanox Pharma B.V.		12/10/1998		
C S	WO 99/10494	A2	Genentech, Inc.		03/04/1999		
C T	WO 01/81417	A2	Biogen, Inc.		11/01/2001		
C U	WO 02/02641	A1	Human Genome Sciences, Inc.		01/10/2002		
C V	WO 02/38766	A2	ZymoGenetics, Inc.		05/16/2002		
C W	WO 02/092620	A2	Amgen, Inc.		11/21/2002		
C X	WO 02/094852	A2	ZymoGenetics, Inc.		11/21/2002		
C Y	WO 02/16411	A2	Human Genome Sciences, Inc.		02/28/2002		
C Z	WO 02/24909	A2	Biogen, Inc.		03/28/2002		
D A	WO 03/016468	A2	Eli Lilly and Company		02/27/2003		
D B	WO 03/030833	A2	Amgen Inc.		04/17/2003		
D C	WO 03/33658	A2	Human Genome Sciences, Inc.		04/24/2003		

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action of a foreign patent office or a written translation of the foreign patent document or information derived from the foreign patent document.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation *
		Office	Application or Patent Number	Kind Code			
D D	WO	03/55979	A2	Human Genome Sciences, Inc.	07/10/2003		
D E	WO	03/089569	A2	Eli Lilly and Company	10/30/2003		
D F	WO	04/058309	A1	Human Genome Sciences, Inc.	07/15/2004		
D G	WO	07/123765		Yu et al.	11/01/2007		
D H	WO	07/142667		Chevrier et al.	12/13/2007		
D I	EP	0 439 095	A2	Bristol-Myers Squibb Company	07/31/1991		
D J	EP	1 157 110	A1	Human Genome Sciences, Inc.	11/28/2001		
D K	EP	1 294 769	A2	Human Genome Sciences, Inc.	03/26/2003		
D L	EP	1 294 949	A2	Human Genome Sciences, Inc.	03/26/2003		
D M	EP	1 309 718	A2	Human Genome Sciences, Inc.	05/14/2003		
D N	EP	1 456 347	A2	Human Genome Sciences, Inc.	09/15/2004		
D O	EP	1 507 793	A1	Human Genome Sciences, Inc.	02/23/2005		
D P	EP	1 577 391	A1	Human Genome Sciences, Inc.	09/21/2005		
D Q	EP	1 860 190	A2	Human Genome Sciences, Inc.	11/28/2007		

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
D R		Biogen's Observations in preparation for oral proceedings in defense of the Opposition of EP Patent No. 1146892 lodged by Merck Serono, S.A., and Human Genome Sciences, Inc. The Observations in preparation for oral proceedings was filed in the European Patent Office on January 19, 2007.	
D S		Declaration of Dr. Fritz Melchers dated December 1, 2006 in support of Browning et al. in Patent Interference No. 105,485.	
D T		Declaration of Dr. Mark S. Schlissel dated December 1, 2006 in support of Browning et al. in Patent Interference No. 105,485.	
D U		Second Declaration of Dr. Mark S. Schlissel dated February 8, 2007 in support of Browning et al. in Patent Interference No. 105,485.	
D V		Third Declaration of Dr. Mark S. Schlissel dated April 15, 2007.	
D W		Declaration of Dr. Randolph J. Noelle dated February 12, 2007 in support of Yu et al. in Patent Interference No. 105,485.	
D X		Declaration of Dr. Rodger G. Smith dated and filed on December 14, 2004.	
D Y		Second Declaration of Dr. Rodger G. Smith dated and filed on August 4, 2005.	
D Z		Declaration of Dr. Georg Friedrich Melchers dated January 19, 2007 filed in support of EP Patent No. 1146892 in the Opposition to EP Patent No. 1146892 lodged by Merck Serono, S.A., and Human Genome Sciences, Inc.	
E A		Declaration of Dr. Carl F. Ware dated and filed on April 16, 2007.	
E B		Declaration of Dr. Raif S. Geha dated and filed on April 16, 2007.	
E C		Declaration of Patent Interference No. 105,485 between U.S. Application No. 09/589,288 and U.S. Patent No. 6,869,605.	
E D		Genbank Accession No. P01374 (07/24/1980), July 1, 1989	
E E		Genbank Accession No. CAA25649 (07/12/1993).	
E F		HGS Backgrounder, "B Lymphocyte Stimulator" dated October 30, 2000.	
E G		HGS Backgrounder "Systemic Lupus Erythematosus" dated November 1, 2000.	

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office. The information may be handwritten or typed. The English translation or abstract must be submitted in a separate document.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
E H		HGS Backgrounder "Immunglobulin-A-Deficiency" dated September 2001.	
E I		HGS Press Release "Human Genome Sciences Announces the Discovery of a Novel Immune Stimulant" dated July 8, 1999.	
E J		HGS Press Release "Human Genome Sciences Announces Advance in Hodgkins Lymphoma" dated July 14, 1999.	
E K		HGS Press Release "New Anti-Angiogenic Proteins Discovered" dated August 5, 1999.	
E L		HGS Press Release "Human Genome Sciences Reports 1999 Financial Results" dated February 10, 2000.	
E M		HGS Press Release "Human Genome Sciences Reports First Quarter Financial Results" dated April 27, 2000.	
E N		HGS Press Release "Human Genome Sciences and Cambridge Antibody Technology Commit to Exclusive Development of Anti-BLyS Antibodies" dated October 30, 2000.	
E O		HGS Press Release "High Levels of BlyS Implicated in Lupus and Rheumatoid Arthritis Patients" dated October 30, 2000.	
E P		HGS Press Release "Human Genome Sciences and Dow Agree to Develop HGS' Radiolabeled B-Lymphocyte Stimulator" dated October 30, 2000.	
E Q		HGS Press Release "Human Genome Sciences Reports Financial Results for Fourth Quarter and Full Year 2000" dated February 15, 2001.	
E R		HGS Press Release "Human Genome Sciences Completes Construction of Antibody Manufacturing Facility" dated February 21, 2001.	
E S		HGS Press Release "Human Genome Sciences Receives Orphan Drug Designation for BlyS Therapeutic Protein for Treatment of Common Variable Immunodeficiency" dated February 27, 2001.	
E T		HGS Press Release "Human Genome Sciences Breaks Ground for a Large Scale Manufacturing Plant" dated October 17, 2001.	
E U		HGS Press Release "Human Genome Sciences Initiates Trial of a New Drug for Systemic Lupus Erythematosus and Other Autoimmune Diseases" dated November 1, 2001.	
E V		HGS Press Release "Human Genome Sciences Data Support Potential of Lymphostat-B as Treatment for Autoimmune Diseases" dated November 14, 2001.	
E W		HGS Press Release "Human Genome Sciences Presents Data as American Society of Hematology Meeting" dated December 9, 2001.	
E X		HGS Press Release "Human Genome Sciences Files Investigational New Drug Application for Lymphorad131" dated January 23, 2002.	
E Y		HGS Press Release "Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2001" dated February 14, 2002.	
E Z		HGS Press Release "Human Genome Sciences Provides Update of Company Progress" dated April 30, 2002.	
F A		HGS Press Release "Human Genome Sciences Announces Clearance of Investigational New Drug Application for Lymphorad131, A New Anticancer Drug for the Treatment of B-Cell Tumors" dated May 14, 2002.	
F B		HGS Press Release "Human Genome Sciences Describes Activity of New cancer Drug at American Society of Clinical Oncology Meeting" dated May 20, 2002.	
F C		HGS Press Release "Human Genome Sciences and Cambridge Antibody Technology Commit to Exclusive Development of Antibody to Trial Receptor-2" dated May 20, 2002.	
F D		HGS Press Release "Human Genome Sciences Announces Second Quarter 2002 Financial Results" dated July 25, 2002.	

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action of a foreign patent office or other authority that issued the reference. The English version of the reference must be the primary version.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	F E	HGS Press Release "Human Genome Sciences Reports Progress in Clinical Trials of Five Drugs at JP Morgan H&Q Conference" dated January 6, 2003.	
	F E	HGS Press Release "Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2002" dated February 14, 2003.	
	F G	HGS Press Release "Results of Phase 1 Clinical Trial Demonstrate that Lymphostat-B™ is Safe and Biologically Active in Patients with Systemic Lupus Erythematosus" dated April 21, 2003.	
	F H	HGS Press Release "Human Genome Sciences Reports Financial Results for First Quarter of 2003" dated April 24, 2003.	
	F I	HGS Press Release "Human Genome Sciences Provides Update of Company Progress" dated May 12, 2003.	
	F J	HGS Press Release "Human Genome Sciences Updates Progress of Clinical Programs at Bio 2003" dated June 25, 2003.	
	F K	HGS Press Release "Human Genome Sciences Initiates Phase 2 Clinical Trial of Lymphostat-B™ for the Treatment of Systemic Lupus Erythematosus" dated September 25, 2003.	
	F L	HGS Press Release, "Human Genome Sciences Reports Results of Phase 1 Clinical Trial of Lymphostat-B™ in Patients with Systemic Lupus Erythematosus" dated October 28, 2003.	
	F M	HGS Press Release "Human Genome Sciences Reports Third Quarter 2003 Financial Results" dated October 28, 2003.	
	F N	HGS Press Release "Human Genome Sciences Reports Interim Results of Phase 1 Clinical Trials of Lymphorad™131 at 45th Annual Meeting of the American Society of Hematology" dated December 9, 2003.	
	F O	HGS Press Release "Human Genome Sciences Initiates Phase 2 Clinical Trial of Lymphostat-B™ for the Treatment of Rheumatoid Arthritis" dated January 8, 2004.	
	F P	HGS Press Release "Human Genome Sciences Updates Progress of Six Drugs in Clinical Trials at JPMorgan Conference" dated January 12, 2004.	
	F Q	HGS Press Release "Human Genome Sciences Reports Financial Results for Fourth Quarter and Full Year 2003" dated February 10, 2004.	
	F R	HGS Press Release "Human Genome Sciences Announces Selection of Lymphostat-B™ for Participation in FDA's Continuous Marketing Application Pilot 2 Program" dated March 4, 2004.	
	F S	HGS Press Release "Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of Lymphostat-B™ for the Treatment of Rheumatoid Arthritis" dated July 29, 2004.	
	F T	HGS Press Release "Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of Lymphostat-B™ for the Treatment of Systemic Lupus Erythematosus" dated July 29, 2004.	
	F U	HGS Press Release "Human Genome Sciences Reports on Progress of Clinical Trials and Announces Goals for 2005 at JPMorgan Healthcare Conference" dated January 10, 2005.	
	F V	HGS Press Release "Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of Lymphostat-B™ in Patients with Rheumatoid Arthritis" dated April 6, 2005.	
	F W	HGS Press Release "GlaxoSmithKline Exercises Option to Lymphostat-B™" dated July 7, 2005.	

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office or counterfeited or forged document or record of a foreign patent office or a document or record of a foreign patent office or a record of a foreign patent office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
F X		HGS Press Release "Human Genome Sciences to Sponsor Conference Call to Discuss Phase 2 Clinical Results of Lymphostat-B™ in Systemic Lupus Erythematosus" dated October 5, 2005.	
F X		HGS Press Release "Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of Lymphostat-B™ in Patients with Systemic Lupus Erythematosus" dated October 5, 2005.	
F Z		HGS Press Release "Human Genome Sciences Reports on Progress Toward Commercialization and Announces 2006 Goals at JPMorgan Healthcare Conference" dated January 10, 2006.	
G B		HGS Press Release "Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of Lymphostat-B™ in Systemic Lupus Erythematosus" dated June 22, 2006.	
G B		Preliminary Non-Binding Decision of the Opposition Division and Summons to attend Oral Proceedings issued by the European Patent Office on October 2, 2006 in the matter of Human Genome Sciences' and Serono's Opposition of EP 1 146 892.	
G C		Minutes of the Oral Proceedings before the Opposition Division, issued by the European Patent Office on April 2, 2007 in the matter of Human Genome Sciences' and Serono's Opposition of EP 1 146 892.	
G D		ACOSTA-RODRIGUEZ et al., <i>Eur. J. Immunol.</i> , 37:990-1000 (2007).	
G E		BADR et al., <i>Blood</i> , 111(5):2744-2754 (2008).	
G F		BERNSTEIN et al., <i>Cancer Res.</i> , 50:1017s-1021s (1990).	
G G		BINARD et al., <i>Journal of Autoimmunity</i> , 30:63-67 (2008).	
G H		BOSELLO et al., <i>Int. J. Immunopathol. Pharmacol.</i> , 20(1):1-8 (2007).	
G I		BUHLMANN et al., <i>J. Clinical Immunology</i> , 16(2) (1996).	
G J		CALICETI et al., <i>Bioconjug. Chem.</i> , "Biopharmaceutical Properties of Uricase Conjugated to Neutral and Amphiphilic Polymers," 10:638-646 (1999).	
G K		CANCRO, <i>Immunological Reviews</i> , 202:237-249 (2004).	
G L		CARSWELL et al., <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 72(9):3666-3670 (1975).	
G M		CERUTTI et al., <i>Immunology and Cell Biology</i> , "Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching," 83:554-562 (2005).	
G N		CHANG, <i>Blood</i> , "A role for BLyS in this activation of innate immune cells," 108(8):2687-94 (2006).	
G O		CHATHAM et al., "Belimumab (Fully Human Monoclonal Antibody to BLyS) Improved or Stabilized Systemic Lupus Erythematosus (SLE) Disease Activity Over 3 Years of Treatment," Poster presented at ACT/ACHP Annual Scientific Meeting, October 24-29, 2008 (San Francisco, CA).	
G P		COHEN, <i>Fundamental Immunology</i> , Paul ed. Lippincott-Raven Philadelphia, PA, 1999, chapter 33:1067-1088.	
G Q		COUZIN, <i>Science</i> , "Magnificent Obsession," 307:1712-1715 (2005).	
G R		CRAGG et al., B Cell Trophic Factors and B Cell Antagonism in Autoimmune Disease "The Biology of CD20 and Its Potential as a Target for mAb Therapy," pp 140-174 (2005).	
G S		CULL, <i>Protocols in Molecular Biology</i> , Appendix 2.A.2.5, Supp. 35, John Wiley & Sons (1989).	
G T		CULL et al., <i>Proc. Natl. Acad. Sci. USA</i> , "Screening for receptor ligands using large libraries of peptides limited to the C terminus of the las repressor," 89:1865-1869 (1992).	

Examiner Signature		Date Considered
--------------------	--	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action in a foreign language. A statement that the reference is not in English or that it is not available in English is not sufficient evidence for the English language.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041

Client Reference No. PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
GU	CWIRLA et al., <i>Proc. Natl. Acad. Sci. USA</i> , "Peptides on phage: A vast library of peptides for identifying ligands," 87:6378-6382 (1990).		
GV	CZUCZMAN et al., <i>J. Clin. Oncology</i> , 11(10):2021 (1993).		
GW	DAVIES, <i>Nature Genetics</i> , "The EST express gathers speed," 364:554 (1993).		
GX	DENARDO et al., <i>Cancer Res.</i> , 50:1014s (1990).		
GY	DEVLIN, <i>Science</i> , "Random Peptide Libraries: A Source of Specific Protein Binding Molecules," 249:404-406 (1990).		
GZ	ECK et al., <i>J Biol. Chem.</i> , 264(29):17595-17605 (1989).		
HA	EGNER, <i>J. Clin. Pathol.</i> , "The use of laboratory tests in the diagnosis of SLE," 53(6):424-32 (2000).		
HB	FALINI et al., <i>Blood</i> , 85:1-14 (1995).		
HC	FELICI, <i>J. Mol. Biol.</i> , "Selection of Antibody Ligands from a Large Library of Oligopeptides Expressed on a Multivalent Exposition Vector," 222:301-310 (1991).		
HD	FELL et al., <i>J. Immunol.</i> , "Genetic Construction And Characterization Of A Fusion Protein Consisting Of A Chimeric F(ab') With Specificity For Carcinomas And Human IL-2," 146:2446-2452 (1991).		
HE	FISHMAN et al., <i>Nature</i> , "A new grammar for drug discovery," 437:491-493 (2005).		
HF	FODOR, <i>Nature</i> , "Multiplexed biochemical assays with biological chips," 364:555-556 (1993).		
HG	FU et al., <i>Blood</i> , 107(11):4540-4548 (2006).		
HH	FURIE et al., <i>Arthritis Res. & Therapy</i> , "Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLYs) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus," 10(5):1-15 (2008).		
HI	GILLIES et al., <i>Proc. Natl. Acad. Sci. USA</i> , "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells," 89:1428-1432 (1992).		
HJ	GOLUB et al., eds., <i>Immunology A Synthesis</i> , Sinauer Assoc., Inc., p. 134 (1991).		
HK	GRUSS, <i>Blood</i> , "Tumor necrosis factor ligand superfamily; Involvement in the pathology of malignant lymphomas," 85(12):3378-404 (1995).		
HL	GRUSS, <i>Int. Jour. Clin. Lab. Res.</i> , "Regulation of murine B cell growth and differentiation by CD30 ligand," 26:143-159 (1996).		
HM	HABERMAN, <i>Genetic Engineering News</i> , "Strategies to Move Beyond Target Validation," 25(21):36 (2005).		
HN	HAHNE et al., <i>J. Exp. Med.</i> , "APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," 188(6):1185-90 (1998).		
HO	HAMMARSTROM et al., <i>Clin. Exp. Immunol.</i> , "Selective IgA deficiency (StgAD) and common variable immunodeficiency (CVID)," 120(2):225-31 (2000).		
HP	HAN, et al., <i>J. Immunol.</i> , 155:556-567 (1995).		
HQ	HE et al., <i>J. Immunol.</i> , "Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLYS and APRIL," 172(5):3268-3279 (2004).		
HR	HE et al., <i>J. Immunol.</i> , "HIV-1 Envelope Triggers Polyclonal Ig Class Switch Recombination through a CD40-Independent Mechanism Involving BAFF and C-Type Lectin Receptors," 176:3931-3941 (2006).		
HS	HILL et al., <i>Molec. Aspects Med.</i> , 17:455-509 (1996).		
HT	HOUGHTEN, <i>Bio/Techniques</i> , "The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides," 13:412-421 (1992).		

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action of a foreign patent office. The Commissioner or his/her designee may accept a statement of relevance from the foreign patent office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
HU	HWANG et al., <i>J. Mol. Cell Cardiol.</i> , "Single Pass Sequencing of a Unidirectional Human Fetal Heart cDNA Library to Discover Novel Genes of the Cardiovascular System," 26:1329-1333 (1994).		
HV	IGLESIAS et al., <i>Allergol. Immunopathol. Review</i> , "Common Variable Immunodeficiency," 29:113-118 (2001).		
HW	JIANG et al., <i>Immunogenetics</i> , "Polymorphism and chromosomal mapping of the mouse gene for B-cell activating factor belonging to the tumor necrosis factor family (Baff) and association with the autoimmune phenotype," 53(9):810-813 (2001).		
HX	JONES et al., <i>Nature</i> , 388:225-228 (1989).		
HY	JUWEID et al., <i>Cancer Res.</i> , 55:5899s (1995).		
HZ	KABAT et al., <i>Sequences of Proteins of Immunological Interest</i> , Fourth Edition, pp. 44, 53-54, 63, 69-70 and 76 (1987).		
IA	KAPAS et al., <i>Amer. J. Physiology</i> , "Tumor necrosis factor- β induces sleep, fever, and anorexia," 263(3):703-707 (1992).		
IB	KELSOE et al., <i>Nature</i> , 279:333-334 (1979).		
IC	KELSOE et al., <i>J. Exp. Med.</i> , 151:289-300 (1980).		
ID	KENNELL, <i>Prog. Nucleic Acid. Res. Mol. Biol.</i> , "Principles and practices of nucleic acid hybridization," 11:259-301 (1971).		
IE	KERN, <i>Blood</i> , "Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway," 103(2):679-88 (2004).		
IF	KESSEL et al., <i>Clinical and Experimental Immunology</i> , "Increased susceptibility of cord blood B lymphocytes to undergo spontaneous apoptosis," 145:563-570 (2006).		
IG	KNOX et al., <i>Clin. Cancer Res.</i> , 2:457 (1996).		
IH	KOLLER et al., <i>Proc. Natl. Acad. Sci. USA</i> , "Inactivating the (32-microglobulin locus in mouse embryonic stem cells by homologous recombination," 86:8932-8935 (1989).		
II	KOO et al., <i>FEMS Microbiology Letters</i> , "Cloning of a novel crystal protein gene cryIK from <i>Bacillus thuringiensis</i> subsp. <i>Morrisoni</i> ," 134:159-164 (1995).		
IJ	KREITMAN, <i>Expert Opn. Biol. Ther.</i> , "Recombinant Immunotoxins for the Treatment of Hematological Malignancies," 4(7):1115-1128 (2004).		
IK	KRUMBHOLZ et al., <i>J. Exp. Med.</i> , "BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma," 201(2):195-200 (2005).		
IL	KWON et al., <i>J. Biol. Chem.</i> , "Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand," 274(10): 6056-61 (1999).		
IM	LAM, <i>Nature</i> , "A new type of synthetic peptide library for identifying ligand-binding activity," 354: 82-84 (1991).		
IN	Lexikon der Medizin "Hypertension."		X
IO	LOONEY, <i>Rheumatology</i> , "B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis," 44 (Suppl. 2): ii13-ii17 (2005).		
IP	LYU et al., <i>Mol. Cancer Ther.</i> , "The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BlyS receptors BAFF-R, TACI, and BCMA," 6(2):460-470 (2007).		
IQ	MACKAY, <i>Curr. Dir. Autoimmun.</i> , "The BAFF/APRIL system: an important player in systemic rheumatic diseases," 8:243-65 (2006).		
IR	MACKAY, <i>Semin. Immunol.</i> , "The role of the BAFF/APRIL system on T cell function," 18:284-9 (2006).		

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action of a foreign patent office. Information in this section is not to be used in determining the scope of protection for the claims in this application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

Sheet 9 of 22

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
IS	MALVAR et al., <i>Genetics</i> , "The CCR4 Protein from <i>Saccharomyces cerevisiae</i> Contains a Leucine-Rich Repeat Region Which Is Required for its Control of ADH2 Gene Expression," 132:951-962 (1992).		
IT	MAURI et al., <i>Immunity</i> , "LIGHT, a New member of the TNF Superfamily, and Lymphotoxin α are Ligands for Herpesvirus Entry Mediator," 8(1):21-30 (1998).		
IU	McGHEE, <i>BMC Pediatr.</i> , "Clinical utility of antinuclear antibody tests in children," 4:13 (2004).		
IV	MELCHERS, <i>Ann. Rheum. Dis.</i> , "Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease," 62 Supp. 2:ii25-27 (2003).		
IW	MOREAUX, <i>Blood</i> , "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone," 103(8):3148-57 (2004).		
IX	MORENS et al., <i>J. Gen. Virol.</i> , 68:91-98 (1987).		
IY	MORPURGO et al., <i>Appl. Biochem. Biotechnol.</i> , "Covalent Modification of Mushroom Tyrosinase with Different Amphiphic Polymers for Pharmaceutical and Biocatalysis Applications," 56:59-72 (1996).		
IZ	NAKAMURA et al., <i>Immunol. Lett.</i> , "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells," 39:91-99 (1994).		
JA	NEDWIN et al., <i>J. Immunol.</i> , "Effect Of Interleukin 2. Interferon- γ , And Mitogens On The Production Of Tumor Necrosis Factors α and β ," 135(4):2492-7 (1985).		
JB	NIMMANAPALLI, <i>Blood</i> , "The growth factor fusion construct containing B-lymphocyte stimulator (BlyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells," 109(6):2557-64 (2007).		
JC	NOVAK, <i>Blood</i> , "Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival," 100:2973-9 (2002).		
JD	NOVAK et al., <i>Blood</i> , 103:689-694 (2004).		
JE	OTTEN, <i>Proc. Natl. Acad. Sci. U.S.A.</i> , "Nerve growth factor induces growth and differentiation of human B lymphocytes," 86:10059-63 (1989).		
JF	PEITISCH et al., <i>International Immunology</i> , 5(2):233-238 (1993).		
JG	PRESS, O.W. "Malignant Lymphomas, Including Hodgkin's Disease: Diagnosis, Management, and Special Problems," Chapter 9 Kluwer Academic Publishers. ed. B. Dana (1993).		
JH	RETH et al., <i>Nature</i> , 290:257-259 (1981).		
JI	ROSEN et al., <i>J. Clin. Oncol.</i> 5:562 (1987).		
JJ	ROTH, <i>Cell Death Differ.</i> , "APRIL, a new member of the tumor necrosis family, modulates death ligand-induced apoptosis," 8:403-410 (2001).		
JK	SAXON et al., <i>Immunology</i> , "Long-term administration of 13-cis retinoic acid in common variable immunodeficiency, circulating interleukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production," 80(3):477-87 (1993).		
JL	SCAPINI et al., <i>J. Exp. Med.</i> , "G-CSF-stimulated Neutrophils Are a Prominent Source of Functional BlyS," 197(3):297-302 (2003).		
JM	SCHIEMANN et al., <i>Science</i> , "An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway," 293(5537):2111-2114 (2001).		
JN	SCOTT et al., <i>Science</i> , "Searching for Peptide Ligands with an Epitope Library," 249:386-390 (1990).		
JO	SCOTT, et al., <i>Current Opinion in Immunology</i> , 9:717-722 (1997).		

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action in a foreign patent office or other international organization or a statement that the reference is not translatable.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No	PF343P3C5

Sheet 10 of 22

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published	Translation *
J P		SCHNEIDER, <i>Current Opinion in Immunology</i> , 17:282-289 (2005).	
J Q		SCHWARTZ et al., <i>Fundamental Immunology</i> , Paul ed., Raven Press, NY. NY., pp. 837 (1989).	
J Q		SEVACH <i>Fundamental Immunology</i> , Paul ed., Lippincott-Raven Philadelphia, PA, chapter 34, pp. 1089-1125 (1999).	
J S		SHANEBECK, <i>Eur. J. Immunol.</i> , "Regulation of murine B-cell growth and differentiation by CD30 ligand," 25(8):2147-53 (1995).	
J T		SHOOP et al., <i>Proceedings of the Twenty-Seventh Annual Hawaii International Conference on System Sciences</i> , "Automating and Streamlining Inference of Function of Plant ESTs within a Data Analysis System" Extended Abstract (1994)	
J U		SMITH et al., <i>Cell</i> , 73:1349-1360 (1993).	
J V		STITES et al., eds., <i>Basic and Clinical Immunology</i> , Chap. 24, pp. 322-334 (1991).	
J W		SUDA et al., <i>Cell</i> , "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family," 75(6):1169-78 (1993).	
J X		SUTHERLAND et al., <i>Pharmacology and Therapeutics</i> , "Targeting BAFF: Immunomodulation for autoimmune diseases and lymphomas," 112:774-786 (2006).	
J Y		SWINDELL et al., <i>Internet for the Molecular Biologist</i> , Horizon Scientific Press: Portland, pp 55-149 (1996).	
J Z		TAI et al., <i>Cancer Res.</i> , "Role of B-Cell-Activating Factor in the Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment," 66(13):6675-6682 (2006).	
K A		TESORIERO, <i>Wall Street Journal</i> , "Drugs in testing show promise for treating lupus," retrieved December 21, 2007 from http://www.post-gazette.com/pf/07023/756127-28.stm .	
K B		THOMPSON et al., <i>Science</i> , "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF," 293(5537):2108-2111 (2001).	
K C		TUMA, <i>J. Natl. Cancer Inst.</i> , "Phase I Antibody Risks, Trial Safety Examined," 98(14):956-958 (2006).	
K D Yan		YAN et al., <i>Nature Immunology</i> , "Identification of a receptor for BlyS demonstrates a crucial role in humoral immunity," 1(1):37-41 (2000).	
K E		VANDENBERGHE et al., <i>Biochemistry</i> , "The Primary Structures of the Low-Redox Potential Diheme Cytochromes c from the Phototrophic Bacteria <i>Rhodobacter sphaeroides</i> and <i>Rhodobacter adriaticus</i> Reveal a New Structural Family of c-Type Cytochromes," 37:13075-13081 (1998).	
K F		VORBJEV et al., <i>Nucleosides & Nucleotides</i> , "Oligonucleotide Conjugated to Linear and Branched High Molecular Weight Polyethylene Glycol as Substrates," 18:2745-2750(1999).	
K G		WALDMANN et al., <i>Ann. Intern. Med.</i> , 116:148 (1992).	
K H		WALDSCHMIDT et al., <i>Science</i> , "Long live the Mature B Cell - a BAFFling Mystery Resolved," 293:2012-2013 (2001).	
K I		WARE, <i>Cytokine & Growth Factor Reviews</i> , "The TNF Superfamily," 14:181-184 (2003).	
K J		WILEY et al., <i>Immunity</i> , "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," 3(6):673-82 (1995).	
K K		WILLIAMS-BLANGERO et al., <i>PNAS</i> , "Genes on chromosomes 1 and 13 have significant effects on Ascaris infection," 99(8):5533-5538 (2002).	
K L		WINTER et al., <i>Nature</i> , "Man-made antibodies," 349:293-299 (1991).	
K M		YE et al., <i>Eur. J. Immunol.</i> , "BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses," 34(10):2750-9 (2004).	

Examiner Signature	Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office or a document that is relied on in the foreign proceeding for the basis of the reference.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city, and/or country where published.	Translation *
K N	ZGANIACZ et al., <i>J. Clin. Invest.</i> "TNF- α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection," 113(3):401-413 (2004).		
K O	ZHOU et al., <i>Blood</i> , "Therapeutic Potential of Antagonizing BLyS for Chronic Lymphocytic Leukemia," 98(11):808A (2001).		
K P	<i>Arthritis Rheum.</i> , "The American College of Rheumatology Response Criteria for Systemic Lupus Erythematosus Clinical Trials," 50(11):3418-3428 (2004).		
K Q	"Guideline on Production and Quality Control of Monoclonal Antibodies and Related Substances", issued by European Medicines Agency on April 5, 2007.		
K R	CAT News Release "Cambridge Antibody Technology and Human Genome Sciences Form Alliance in Therapeutic Antibodies" dated August 10, 1999.		
K S	CAT News Release "CAT and Human Genome Sciences ("HGS") Create Major Alliance Dedicated to Developing Human Antibody Therapeutics Against Genomics Targets" dated March 1, 2000.		
K T	CAT News Release "Cambridge Antibody Technology Group plc ("CAT") Open Offer & International Offering to Raise £100 Million in a New Share Issue" dated March 7, 2000.		
K U	CAT News Release "Cambridge Antibody Technology: Clinical Trials Update" dated January 12, 2004.		
K V	CAT News Release "Cambridge Antibody Technology Reports Recent Progress In Licensed Product Candidates" dated October 5, 2005.		
K W	HGS Press Release "Cambridge Antibody Technology and Human Genome Sciences Form Alliance in Therapeutic Antibodies" dated August 10, 1999.		
K X	HGS Press Release "Human Genome Sciences and Abgenix Enter a Broad Collaboration to Create Fully Human Antibody Therapeutics" dated December 1, 1999.		
K Y	HGS Press Release "Human Genome Sciences to Initiate Human Clinical Trials of BLyS" dated June 23, 2000.		
K Z	HGS Press Release "Human Genome Sciences and Medarex Announce Collaboration" dated July 25, 2001.		
L A	HGS Press Release "Human Genome Sciences Announces Trial For Treatment of Immunoglobulin-A Deficiency" dated September 19, 2001.		
L B	International Search Report issued in PCT Application No. PCT/US06/38756, dated July 14, 2008.		
L C	International Search Report issued in PCT Application No. PCT/US07/08021, dated August 4, 2008.		
L D	Human Genome Sciences Press Release, dated November 1, 2001.		
L E	Declaration of Interference 105,485, Paper 1 filed in the United States Patent Office on August 15, 2006.		
L F	Order Bd.R 104(c) in Patent Interference 105,485 dated April 19, 2007.		
L G	Order Bd.R 104(c) in Patent Interference 105,485 dated April 23, 2007.		
L H	Order - Priority times Bd.R. 104(c) in Patent Interference 105,485 dated April 19, 2007.		
L I	Decision on Preliminary Motions in Patent Interference 105,485. Filed in the United States Patent Office on August 31, 2007.		
L J	Yu Priority Statement in Patent Interference 105,485. Filed in the United States Patent Office on December 1, 2006.		
L K	Browning Priority Statement in Patent Interference 105,485. Filed in the United States Patent Office on December 1, 2006.		

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action or a brief statement of the reference in English. The information contained in this document is not a substitute for a search or examination for patentability.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	09/589,288
				Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	PF343P3C5
Sheet	12	of	22		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
L L		Browning Amended Priority Statement in Patent Interference 105,485. Filed in the United States Patent Office on December 12, 2006.	
L M		Claims involved in Patent Interference 105,485 submitted by Human Genome Sciences . Filed in the United States Patent Office on August 15, 2006.	
L N		Browning Notice of Non-filing 135(b) submitted by Biogen, Inc. in Patent Interference 105,485. Filed in the United States Patent Office on November 16, 2006.	
L O		Browning Observation 1 filed by Biogen, Inc. in Patent Interference 105,485. Filed in the United States Patent Office on February 12, 2007.	
L P		Yu reply and Browning Observation on reply in Patent Interference 105,485. Filed in the United States Patent Office on April 16, 2007 and April 30, 2007.	
L Q		Re-declaration of Interference in Patent Interference 105,485. Filed in the United States Patent Office on August 31, 2007.	
L R		Yu Exhibit List submitted by Human Genome Sciences, Inc. in Patent Interference 105,485 as of November 28, 2007.	
L S		Browning Demonstrative Exhibits submitted by Biogen, Inc. in Patent Interference 105,485.	
L T		Browning combined motions 2 to10 submitted by Biogen, Inc. in Patent Interference 105,485.	
L U		Browning combined replies submitted by Biogen, Inc. in Patent Interference 105,485.	
L V		Yu Demonstrative Exhibits submitted by Human Genome Sciences, Inc. in Patent Interference 105,485.	
L W		Yu combined motions 1 to 6 submitted by Human Genome Sciences, Inc. in Patent Interference 105,485.	
L X		Yu combined oppositions 1 to 7 submitted by Human Genome Sciences, Inc. in Patent Interference 105,485.	
L Y		Declaration of Amy Orr dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
L Z		Declaration of Bieigie Lee dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M A		Declaration of David LaFleur dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M B		Declaration of Ding Liu dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M C		Declaration of Ellie Bouffard dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M D		Marked-up copy of Declaration of Dr. Fritz Melchers dated January 16, 2007 in support of Browning et al. in Patent Interference 105,485.	
M E		Declaration of Dr. Guo-Liang Yu dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M F		Declaration of Jeffrey Carrell dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M G		Declaration of Krystyna Pieri dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M H		Declaration of Laurie Brewer dated November 28, 2007 in support of Yu et al. in Patent Interference 105,485.	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action if a foreign language counterpart, abstract, or version is not provided. The English language version of the reference must be submitted.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
M I		Marked-up copy of Declaration of Dr. Mark S. Schlissel dated December 1, 2006 in support of Browning et al. in Patent Interference 105,485.	
M I		Declaration of Meghan Birkholz dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M K		Declaration of Michael Fannon dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M I		Declaration of Dr. Ornella Belvedere dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M M		Declaration of Dr. Reinhard Ebner dated November 21, 2007 in support of Yu et al. in Patent Interference 105,485.	
M N		Declaration of Scott Conklin dated November 26, 2007 in support of Yu et al. in Patent Interference 105,485.	
M O		Declaration of William Derrick dated November 28, 2007 in support of Yu et al. in Patent Interference 105,485.	
M P		Second Declaration of Dr. Randolph J. Noelle dated November 28, 2007 in support of Yu et al. in Patent Interference 105,485.	
M Q		Declaration of Dr. David Hilbert dated November 27, 2007 in support of Yu et al. in Patent Interference 105,485.	
M R		Declaration of Dr. Paul Moore dated November 26, 2007 in support of Yu et al. in Patent Interference 105,485.	
M S		Transcript of Deposition of Dr. Paul Moore in Patent Interference 105,485 dated January 4, 2008.	
M T		Transcript of Deposition of Dr. David Hilbert in Patent Interference 105,485 dated January 5, 2008.	
M U		Transcript of Deposition of Jeffrey Carrell in Patent Interference 105,485 dated February 12, 2008.	
M V		Transcript of Deposition of Krystyna Pieri in Patent Interference 105,485 dated February 12, 2008.	
M W		Transcript of Deposition of Dr. Reinhard Ebner in Patent Interference 105,485 dated February 15, 2008.	
M X		Transcript of Deposition of Guo-Liang Yu in Patent Interference 105,485 dated January 4, 2008.	
M Y		Transcript of Deposition of Amy Orr in Patent Interference 105,485 dated February 22, 2008.	
M Z		Transcript of Deposition of Dr. Randolph Noelle in Patent Interference 105,485 dated February 26, 2008.	
N A		Transcript of Deposition of Eleanor Bouffard in Patent Interference 105,485 dated February 28, 2008.	
N B		Defendant's Notice of Experiments in Reply submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
N C		Work up experiments in relation to Defendant's Notice of Experiments in Reply submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
N D		Claimant's notice of experiments submitted by Eli Lilly against Human Genome Sciences in UK Revocation suit HC06CO2687.	

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action if a foreign language counterpart, abstract or version is not provided. In the case of a reference from a foreign language, the reference is considered to be in English if the reference is in a language that is a commonly understood language in the United States.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 22

		<i>Complete if Known</i>	
Application Number	09/589,288		
Filing Date	June 8, 2000		
First Named Inventor	Guo-Liang Yu		
Group Art Unit	1647		
Examiner Name	Bridget E. Bunner		
Attorney Docket Number	702041		
Client Reference No	PF343P3C5		

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
N E		Defendant's response to claimant's notice of experiments submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
N E		Alignment of BLyS and Eli Lilly's sequences submitted in UK Revocation suit HC06CO2687 dated November 29, 2007.	
N G		Technician's précis of notice of the notice of experiments submitted in UK Revocation suit HC06CO2687.	
N H		Application Notice submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated November 2, 2006.	
N I		International Preliminary Exam Report submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated December 20, 1998.	
N J		Office communication from European Patent Office submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated May 3, 2002.	
N K		Human Genome Sciences' response to Office communication from European Patent Office submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated May 30, 2002.	
N L		Office communication from European Patent Office submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated January 17, 2003.	
N M		Human Genome Sciences, Inc. response to office communication from European Patent Office submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated January 17, 2003.	
N N		Office Communication European Patent Office submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated June 30, 2004.	
N O		Transcript of Examiner Interview dated October 1, 2004 submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
N P		Human Genome Response to Examiner Interview of October 1, 2004 submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 and dated October 4, 2004.	
N Q		Office Communication European Patent Office submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated October 13, 2004.	
N R		Human Genome Sciences, Inc. response to office communication from European Patent Office submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated November 30, 2004.	
N S		Human Genome Sciences amended claims and specification submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated November 30, 2004.	
N T		Notice of Intent to Grant EP patent No. 0 939 845 submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated January 28, 2005.	
N U		Human Genome Sciences response to Notice of Intent to Grant submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated June 7, 2005.	

Examiner Signature		Date Considered
--------------------	--	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office. The Commissioner may accept other forms of disclosure if they are equivalent to the above forms.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 15 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	N V	Transcript of hearing of November 8, 2006 in UK Revocation suit HC06CO2687.	
	N W	Transcript of hearing of November 9, 2006 in UK Revocation suit HC06CO2687.	
	N X	Defendant's civil evidence act notice submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated June 1, 2007.	
	N Y	Defendant's civil evidence act notice submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated November 29, 2007.	
	N Z	Claimant's civil evidence act notice submitted by Eli Lilly in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated June 1, 2007.	
	O A	Defendant's civil evidence act notice submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687 dated December 7, 2007.	
	O B	Claimant's Further Information concerning the statement of opposition submitted by Eli Lilly in UK Revocation suit HC06CO2687 dated May 4, 2007.	
	O C	Claimant's statement of case relating to SWISS-PROT submitted by Eli Lilly in UK Revocation suit HC06CO2687 dated November 30, 2006.	
	O D	Defendant's conditional application to further amend claim 15 submitted by Human Genome Sciences in UK Revocation suit HC06CO2687.	
	O E	Claimant's grounds for opposition to further amend claim 15 submitted in UK Revocation suit HC06CO2687.	
	O F	Correspondence between Human Genome Sciences and the United Kingdom Patent Office submitted by Eli Lilly in UK Revocation suit HC06CO2687.	
	O G	Defendant's amended response to claimant's request for further information submitted by Human Genome Sciences in UK Revocation suit HC06CO2687.	
	O H	Defendant's response to claimant's notice to admit submitted in UK Revocation suit HC06CO2687.	
	O I	Defendant's response to claimant's second request for further information submitted in UK Revocation suit HC06CO2687.	
	O J	Documents handed up during trial in UK Revocation suit HC06CO2687.	
	O K	Claimant's response to defendant's notice of experiments in reply submitted by Eli Lilly in UK Revocation suit HC06CO2687 dated November 30, 2006.	
	O L	Claims from EP Patent 0 939 804 submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
	O M	Amended claims submitted by Human Genome Sciences in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
	O N	Human Genome Sciences' response to request to attend oral hearings in UK Revocation suit HC06CO2687 dated June 30, 2004.	
	O O	Human Genome Sciences' Opening Arguments in UK Revocation suit HC06CO2687.	
	O P	Human Genome Sciences' Closing Arguments in UK Revocation suit HC06CO2687.	
	O Q	Eli Lilly's Opening Arguments in UK Revocation suit HC06CO2687.	
	O R	Eli Lilly's Closing Arguments in UK Revocation suit HC06CO2687.	
	O S	Order Confirming Claimant's Undertaking Not to Infringe submitted in UK Revocation suit HC06CO2687.	
	O T	Order for Directions submitted in UK Revocation suit HC06CO2687.	
	O U	Order of Mr. Justice Pumfrey submitted in UK Revocation suit HC06CO2687.	
	O V	Order of Mr. Justice Warren submitted in UK Revocation suit HC06CO2687.	

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action or a brief statement indicating the English language version of the document can be found in the search report or action.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	09/589,288
				Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	PF343P3C5
Sheet	16	of	22		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
OW		Particulars of the Claim submitted in UK Revocation suit HC06CO2687.	
OX		Re-reamended grounds of invalidity submitted by Eli Lilly in UK Revocation suit HC06CO2687.	
OY		Statement of Opposition submitted by Eli Lilly in UK Revocation suit HC06CO2687.	
OZ		Defendant Statement of Reasons to amend the claims of EP Patent No. 0 939 804 submitted by Human Genome Sciences in UK Revocation suit HC06CO2687.	
PA		Table of relevant scientific papers submitted in UK Revocation suit HC06CO2687.	
PB		Table of selected passages from EP Patent No. 0 939 804 submitted in UK Revocation suit HC06CO2687.	
PC		BioTherapeutic Overview submitted in UK Revocation suit HC06CO2687.	
PD		Cambridge Antibody Technology website printed March 7, 2007 submitted in UK Revocation suit HC06CO2687.	
PE		EFPtA website printed September 12, 2007 submitted in UK Revocation suit HC06CO2687.	
PF		Eli Lilly website submitted in UK Revocation suit HC06CO2687.	
PG		EMEA 2007 Antibody guidelines submitted in UK Revocation suit HC06CO2687.	
PH		Wikipedia page submitted by Eli Lilly in UK Revocation suit HC06CO2687.	
PI		Mobitech website submitted in UK Revocation suit HC06CO2687.	
PJ		First Expert Report of Dr. Rolf Apweiler dated May 29, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
PK		Second Expert Report of Dr. Rolf Apweiler dated June 23, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
PL		Fourth Expert Report of Dr. Rolf Apweiler dated December 11, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
PM		Witness Statement of Dr. David E. Cash dated November 14, 2006 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
PN		Witness Statement of Christa Pennachio dated April 23, 2007 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
PO		Witness Statement of Christa Pennachio dated May 15, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
PP		Transcripts of trial days 1 to 13 of UK Revocation suit HC06CO2687.	
PQ		Witness Statement of Dr. Stuart Farrow dated June 1, 2007 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
PR		Witness Statement of Dr. William F. Heath dated June 27, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
PS		First Witness Statement of Mark Hodgson dated November 6, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
PT		Second Witness Statement of Mark Hodgson dated November 7, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
PU		First Expert Report of Dr. Andrew C.R. Martin in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
PV		Second Expert Report of Dr. Andrew C.R. Martin in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
PW		First Expert Report of Dr. Randolph Noelle dated June 1, 2007 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office. The statement of relevance must be submitted in English and must be self-explanatory for the Patent Office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

Sheet 17 of 22

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city, and/or country where published.	Translation *
P X		Second Expert Report of Dr. Randolph Noelle dated June 22, 2007 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
P X		First Witness Statement of Dr. Penny X. Gilbert dated November 2, 2006 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
P Z		Second Witness Statement of Dr. Penny X. Gilbert dated November 6, 2006 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
Q A		First Expert Report of Dr. Jeremy Saklatalva dated May 25, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
Q B		Second Expert Report of Dr. Jeremy Saklatalva dated June 27, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
Q C		Third Expert Report of Dr. Jeremy Saklatalva dated November 23, 2007 in support of Eli Lilly in UK Revocation suit HC06CO2687.	
Q D		Witness Statement of Simon Mark Wright dated June 6, 2007 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
Q E		Witness Statement of Elisabeth Gasteiger dated June 12, 2007 in support of Human Genome Sciences in UK Revocation suit HC06CO2687.	
Q F		Declaration of Dr. Thi-Sau Migone dated July 12, 2007 in support of Human Genome Sciences in Opposition of EP Patent No. 1141274.	
Q G		Second Declaration of Carl F. Ware dated January 28, 2008 in support of Browning et al. in Patent Interference 105,485.	
Q H		Minutes of Oral Proceedings dated April 2, 2007 in Opposition of Biogen, Inc. Patent EP 1146892.	
Q I		Biogen Decision dated November 27, 2007 in Opposition of Patent EP 1146892.	
Q J		ZymoGenetics Interlocutory Decision dated November 30, 2007 in Opposition of Patent EP 1141274.	
Q K		ZymoGenetics Preliminary Opinion dated March 15, 2007 in Opposition of Patent EP 1141274.	
Q L		Extended European Search Report, European Application No. 07 01 2741.0 dated February 8, 2008.	
Q M		Grounds of Appeal filed by Merck Serono dated March 27, 2008 in Opposition of Patent EP 1 146 892.	
Q N		Grounds of Appeal submitted by Human Genome Sciences, Inc. on April 13, 2009 in Appeal Case T 18/09-3.3.08 in support of EP Patent 0939804.	
Q O		Human Genome Sciences Observations on Oppositions to EP 0939804 dated April 2, 2008.	
Q P		Auxiliary Requests 1-12 submitted by Human Genome Sciences, Inc. in defense of EP Patent No. 0 939 804 dated May 8, 2008.	
Q Q		Eli Lilly's Submission in Opposition of EP Patent No. 0 939 804 including copies of supporting documents D48-D57. Filed in the European Patent Office on April 2, 2008.	
Q R		Eli Lilly's Submission in Opposition of EP Patent No. 0 939 804 including copies of supporting documents D98-D112. Filed in the European Patent Office on May 30, 2008.	
Q S		Serono's Opposition of EP Patent No. 0 939 804 including copies of supporting documents D1-D27. Filed in the European Patent Office on May 18, 2006.	
Q T		Human Genome Sciences' Observations on the Oppositions against EP Patent No. 0 939 804 including annexes. Filed in the European Patent Office on April 2, 2008.	

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action as it is foreign language counterpart, abstract or version. The English language version or statement of relevance must be independent of the reference from which it is derived.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 18 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	Q U	Declaration of Dr. Andrew Martin and annexes filed in support of Human Genome Sciences' EP Patent No. 0 939 804 dated March 26, 2008 and filed in the European Patent Office.	
	Q V	Declaration of Dr. David Cash and annexes filed in support of Human Genome Sciences' EP Patent No. 0 939 804 dated March 6, 2008 and filed in the European Patent Office.	
	Q W	Declaration of Dr. Randolph Noelle and annexes filed in support of Human Genome Sciences' EP Patent No. 0 939 804 dated March 23, 2008 and filed in the European Patent Office.	
	Q X	Declaration of Dr. Stuart Farrow and annexes filed in support of Human Genome Sciences' EP Patent No. 0 939 804 dated March 25, 2008 and filed in the European Patent Office.	
	Q Y	Declaration of Dr Garnett Herrel Kelsoe III, filed in support of Human Genome Sciences' EP Patent No. 0 939 804 dated April 12, 2009 and filed in the European Patent Office.	
	Q Z	Witness statement of Christa Pange Pennacchio and annexes filed in support of Human Genome Sciences' EP Patent No. 0 939 804 dated March 25, 2008 and filed in the European Patent Office.	
	R A	List of documents, dated May 29, 2008 relied upon in Opposition proceedings against Human Genome Sciences' EP Patent No. 0 939 804.	
	R B	Human Genome Sciences' opposition to Biogen, Inc. EP Patent No. 1 146 892 with annexes C15-C25. Filed in the European Patent Office on May 10, 2004.	
	R C	Serono's opposition to Biogen, Inc. EP Patent No. 1 146 892. Filed in the European Patent Office on May 21, 2004.	
	R D	ZymoGenetics' response to the Oppositions against ZymoGenetics EP Patent No. 1 141 274 filed in the European Patent Office on June 6, 2005.	
	R E	Human Genome Sciences' reply to ZymoGenetics' response to the Oppositions against ZymoGenetics EP Patent No. 1 141 274 filed in the European Patent Office on November 4, 2005.	
	R F	Opposition Division's Preliminary Opinion and annex in the Opposition Proceedings against against ZymoGenetics EP Patent No. 1 141 274 filed in the European Patent Office on March 15, 2007.	
	R G	Second Declaration of Dr. Andrew Martin filed by Human Genome Sciences in support of HGS EP Patent No. 0 939 804. Filed in the European Patent Office and dated May 7, 2008.	
	R H	Declaration of Dr. Penny X. Gilbert filed by Human Genome Sciences in support of HGS EP Patent No. 0 939 804. Filed in the European Patent Office and dated May 8, 2008.	
	R I	Human Genome Sciences Press Release dated December 1, 1999.	
	R J	Transcript of Deposition of Dr. Randolph Noelle in Patent Interference 105,485 dated April 5, 2007.	
	R K	Declaration of Henrik Olsen in support of Yu et al. in Patent Interference 105,485 dated December 16, 2007.	
	R L	Browning opposition and table of content in Patent Interference 105,485. Filed in the United States Patent Office on February 12, 2007.	
	R M	Yu Exhibit 1200 submitted during the Deposition of Eleanor Bouffard in Patent Interference 105,485 dated February 28, 2008.	
	R N	Yu Exhibit 1201 submitted during the Deposition of Eleanor Bouffard in Patent Interference 105,485 dated February 28, 2008.	

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action file or order or decision or other document or information relied upon in the reference from which the reference was taken.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 19 of 22

Complete if Known	
Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	RO	Transcript of a Teleconference in Patent Interference 105,485 dated February 11, 2008	
	RP	Claim Form submitted by Eli Lilly and Company requesting revocation of Human Genome Sciences, Inc. EP Patent 0 939 804. Filed in the United Kingdom Patent Office on July 5, 2006.	
	RQ	Human Genome Sciences, Inc. Defense of EP Patent 0 939 804 filed in the United Kingdom Patent Office on August 3, 2006.	
	RR	Human Genome Sciences, Inc. Patent in suit as proposed to be amended during UK Revocation suit HC06CO2687.	
	RS	Application to Amend Claims filed by Human Genome Sciences, Inc. during UK Revocation suit HC06CO2687 on February 22, 2007.	
	RT	Agreed Statement of Facts regarding the IMAGE EST submitted in UK Revocation suit HC06CO2687.	
	RU	Approved Judgment by Mr. Justice Kitchin in UK Revocation suit HC06CO2687 dated July 31, 2008.	
	RV	Quotations evidencing agreement on the closest prior art, the formulation of the technical problem and its solution by the invention. Filed in the European Patent Office as exhibit D116 in support of Human Genome Sciences' EP Patent No. 0 939 804 on April 13, 2009.	
	RW	Declaration of Dr. Chih-Hung Lo and Exhibits A to L filed in support of Human Genome Sciences' EP Patent No. 1 294 769 dated August 19, 2008 and filed in the European Patent Office.	
	RX	Minutes of the Oral Proceedings before the Opposition Division and the Decision Revoking the European Patent, issued by the European Patent Office on December 3, 2008 in the matter of Eli Lilly and Company's Opposition of EP 0 939 804.	
	RY	Judgment of Kitchin J. in Eli Lilly and Company v Human Genome Sciences, Inc. [2008] EWHC 1903 ("the English revocation action").	
	RZ	HGS Press Release "Human Genome Sciences Reports Phase 2 Results for LYMPHOSTAT-B (Bellimumab) in Patients with Rheumatoid Arthritis," dated November 17, 2005.	
	SA	HGS Press Release "Human Genome Sciences Announces Positive 76-week Results of Phase 2 Clinical Trial of LYMPHOSTAT-B in Systemic Lupus Erythematosus," dated November 14, 2006.	
	SB	Human Genome Sciences' Press Release dated May 30, 2007.	
	SC	Alignment of D41 Shu Figure 1B with D1 Gruss and Dower β -sheets. Filed in the European Patent Office as exhibit D146 in support of Human Genome Sciences' EP Patent No. 0 939 804 on April 13, 2009.	
	SD	Alignment of D10 Schneider Figure 1B with D1 Gruss and Dower β sheets. Filed in the European Patent Office as exhibit D147 in support of Human Genome Sciences' EP Patent No. 0 939 804 on April 13, 2009.	
	SE	Partial Transcript of Costs Hearing in the English Revocation Action (UK Revocation suit HC06CO2687) dated October 17, 2008.	
	SF	Requirement for Restriction/Election issued in U.S. Patent Application No. 11/543,024, dated February 28, 2007.	
	SG	Non-Final Rejection issued in U.S. Patent Application No. 11/543,024, dated July 31, 2007.	
	SH	Final Rejection issued in U.S. Patent Application No. 11/543,024, dated March 5, 2008.	

Examiner Signature _____ Date Considered _____

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action. It is recommended that the English language counterpart be a direct translation of the original document or a summary of the document.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 20 of 22

Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041
Client Reference No.	PF343P3C5

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	SJ	Requirement for Restriction/Election issued in U.S. Patent Application No. 09/932,613, dated April 8, 2003.	
	SJ	Non-Final Rejection issued in U.S. Patent Application No. 09/932,613, dated July 14, 2004.	
	SK	Final Rejection issued in U.S. Patent Application No. 09/932,613, dated April 20, 2005.	
	SJ	Requirement for Restriction/Election issued in U.S. Patent Application No. 11/232,439, dated April 24, 2007.	
	SM	Non-Final Rejection issued in U.S. Patent Application No. 11/232,439, dated May 28, 2008.	
	SN	Requirement for Restriction/Election issued in U.S. Patent Application No. 09/880,748, dated May 7, 2003.	
	SO	Examiner Interview Summary issued in U.S. Patent Application No. 09/880,748, dated June 2, 2003.	
	SP	Non-Final Rejection issued in U.S. Patent Application No. 09/880,748, dated September 14, 2004.	
	SQ	Final Rejection issued in U.S. Patent Application No. 09/880,748, dated May 4, 2005.	
	SR	Advisory Action issued in U.S. Patent Application No. 09/880,748, dated September 28, 2005.	
	SS	Requirement for Restriction/Election issued in U.S. Patent Application No. 10/293,418, dated March 6, 2006.	
	ST	Non-Final Rejection issued in U.S. Patent Application No. 10/293,418, dated June 30, 2006.	
	SU	Requirement for Restriction/Election issued in U.S. Patent Application No. 11/054,515, dated February 15, 2007.	
	SV	Requirement for Restriction/Election issued in U.S. Patent Application No. 11/054,515, dated February 25, 2008.	
	SW	Non-Final Rejection issued in U.S. Patent Application No. 11/054,515, dated July 3, 2008.	
	SX	Final Rejection issued in U.S. Patent Application No. 11/054,515, dated February 24, 2009.	
	SY	Requirement for Restriction/Election issued in U.S. Patent Application No. 11/266,444, dated April 24, 2007.	
	SZ	Non-Final Rejection issued in U.S. Patent Application No. 11/266,444, dated February 28, 2008.	
	TA	Final Rejection issued in U.S. Patent Application No. 11/266,444, dated December 3, 2008.	
	TB	Advisory Action issued in U.S. Patent Application No. 11/266,444, dated February 24, 2009.	
	TC	Requirement for Restriction/Election issued in U.S. Patent Application No. 10/735,865, dated July 12, 2006.	
	TD	Requirement for Restriction/Election issued in U.S. Patent Application No. 10/739,042, dated July 12, 2006.	
	TE	Requirement for Restriction/Election issued in U.S. Patent Application No. 09/589,287, dated February 20, 2001.	
	TF	Non-Final Rejection issued in U.S. Patent Application No. 09/589,287, dated November 6, 2001.	

Examiner Signature

Date Considered

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office. A statement from the applicant or assignee concerning the English language version of the reference may be filed in the form of a declaration.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO		<i>Complete if Known</i>			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/589,288		
(Use as many sheets as necessary)		Filing Date	June 8, 2000		
		First Named Inventor	Guo-Liang Yu		
		Group Art Unit	1647		
		Examiner Name	Bridget E. Bunner		
		Attorney Docket Number	702041		
Sheet 21 of 22		Client Reference No. PF343P3C5			

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city, and/or country where published.	Translation *
TG		Examiner Interview Summary issued in U.S. Patent Application No. 09/589,287, dated November 27, 2001.	
TH		Examiner Interview Summary issued in U.S. Patent Application No. 09/589,287, dated December 21, 2001.	
TI		Notice of Allowance issued in U.S. Patent Application No. 09/589,287, dated December 31, 2001.	
TJ		Requirement for Restriction/Election issued in U.S. Patent Application No. 09/588,947, dated March 8, 2001.	
TK		Non-Final Rejection issued in U.S. Patent Application No. 09/588,947, dated November 26, 2001.	
TL		Notice of Allowance issued in U.S. Patent Application No. 09/588,947, dated July 15, 2002.	
TM		Requirement for Restriction/Election issued in U.S. Patent Application No. 09/589,286, dated December 10, 2001.	
TN		Non-Final Rejection issued in U.S. Patent Application No. 09/589,286, dated June 10, 2002.	
TO		Non-Final Rejection issued in U.S. Patent Application No. 09/589,286, dated December 4, 2002.	
TP		Notice of Allowance issued in U.S. Patent Application No. 09/589,286, dated June 3, 2003.	
TQ		Requirement for Restriction/Election issued in U.S. Patent Application No. 09/589,285, dated February 20, 2001.	
TR		Non-Final Rejection issued in U.S. Patent Application No. 09/589,285, dated November 6, 2001.	
TS		Final Rejection issued in U.S. Patent Application No. 09/589,285, dated September 6, 2002.	
TT		Non-Final Rejection issued in U.S. Patent Application No. 09/589,285, dated October 22, 2003.	
TU		Notice of Allowance issued in U.S. Patent Application No. 09/588,285, dated May 18, 2004.	
TV		Requirement for Restriction/Election issued in U.S. Patent Application No. 11/377,165, dated June 27, 2008.	
TW		Non-Final Rejection issued in U.S. Patent Application No. 11/377,165, dated December 3, 2008.	
TX		Requirement for Restriction/Election issued in U.S. Patent Application No. 11/382,837, dated May 29, 2008.	
TY		Non-Final Rejection issued in U.S. Patent Application No. 11/382,837, dated November 28, 2008.	
TZ		Requirement for Restriction/Election issued in U.S. Patent Application No. 09/929,493, dated December 16, 2002.	
UA		Requirement for Restriction/Election issued in U.S. Patent Application No. 10/270,487, dated June 15, 2004.	
UB		Non-Final Rejection issued in U.S. Patent Application No. 10/270,487, dated February 10, 2005.	
UC		Requirement for Restriction/Election issued in U.S. Patent Application No. 11/054,539, dated January 9, 2007.	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English language abstract, or an English-language version of the search report or action taken by the foreign patent office or technical institution in the foreign country in which the reference was published or examined.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	22	of	22	Client Reference No.	PF343P3C5
-------	----	----	----	----------------------	-----------

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	UD	Non-Final Rejection issued in U.S. Patent Application No. 11/054,539, dated May 2, 2007.	
	UE	Final Rejection issued in U.S. Patent Application No. 11/054,539, dated January 22, 2008.	
	UF	Office Communication from EPO in EP Application No. 07109688.7 mailed May 5, 2008 containing Extended European Search Report mailed September 24, 2007.	
	UG	Response to EP Office Communication in EP Application No. 07109688.7 mailed November 7, 2008.	
	UH	International Preliminary Report on Patentability issued in PCT/US2007/008021 dated October 9, 2008.	

Examiner Signature	/Bridget E. Bunner/	Date Considered	07/10/2009
--------------------	---------------------	-----------------	------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action file for the reference. The document is considered to be in English if it is in English or if it is in another language but the document is annotated in English.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/